<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_OMTN1356 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEgr5 jpg ?>
<?FILEfx1 jpg ?>
<?FILEmmc1 pdf ?>
<?FILEmmc2 xlsx ?>
<?FILEmmc3 pdf ?>
<?FILEsi1 gif ?>
<?FILEsi2 gif ?>
<?FILEsi3 gif ?>
<?FILEsi4 gif ?>
<?FILEsi5 gif ?>
<?FILEsi6 gif ?>
<?FILEsi7 gif ?>
<?FILEsi8 gif ?>
<?FILEsi9 gif ?>
<?FILEsi10 gif ?>
<?FILEsi11 gif ?>
<?FILEsi12 gif ?>
<?FILEsi13 gif ?>
<?FILEsi14 gif ?>
<?FILEsi15 gif ?>
<?FILEsi16 gif ?>
<?FILEsi17 gif ?>
<?FILEsi18 gif ?>
<?FILEsi19 gif ?>
<?FILEsi20 gif ?>
<?FILEsi21 gif ?>
<?FILEsi22 gif ?>
<?FILEsi23 gif ?>
<?FILEsi24 gif ?>
<?FILEsi25 gif ?>
<?FILEsi26 gif ?>
<?FILEsi27 gif ?>
<?FILEsi28 gif ?>
<?FILEsi29 gif ?>
<?FILEsi30 gif ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Mol Ther Nucleic Acids</journal-id>
    <journal-id journal-id-type="iso-abbrev">Mol Ther Nucleic Acids</journal-id>
    <journal-title-group>
      <journal-title>Molecular Therapy. Nucleic Acids</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2162-2531</issn>
    <publisher>
      <publisher-name>American Society of Gene &amp; Cell Therapy</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8479276</article-id>
    <article-id pub-id-type="pii">S2162-2531(21)00210-9</article-id>
    <article-id pub-id-type="doi">10.1016/j.omtn.2021.08.016</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>TSMDA: Target and symptom-based computational model for miRNA-disease-association prediction</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Uthayopas</surname>
          <given-names>Korawich</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>de Sá</surname>
          <given-names>Alex G.C.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Alavi</surname>
          <given-names>Azadeh</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Pires</surname>
          <given-names>Douglas E.V.</given-names>
        </name>
        <email>douglas.pires@unimelb.edu.au</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="aff5" ref-type="aff">5</xref>
        <xref rid="cor2" ref-type="corresp">∗∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Ascher</surname>
          <given-names>David B.</given-names>
        </name>
        <email>david.ascher@unimelb.edu</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="aff4" ref-type="aff">4</xref>
        <xref rid="aff6" ref-type="aff">6</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>1</label>Structural Biology and Bioinformatics, Department of Biochemistry, University of Melbourne, Parkville 3052, VIC, Australia</aff>
      <aff id="aff2"><label>2</label>Systems and Computational Biology, Bio21 Institute, University of Melbourne, Parkville 3052, VIC, Australia</aff>
      <aff id="aff3"><label>3</label>Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne 3004, VIC, Australia</aff>
      <aff id="aff4"><label>4</label>Baker Department of Cardiometabolic Health, Melbourne Medical School, University of Melbourne, Parkville 3010, VIC, Australia</aff>
      <aff id="aff5"><label>5</label>School of Computing and Information Systems, University of Melbourne, Parkville 3052, VIC, Australia</aff>
      <aff id="aff6"><label>6</label>Department of Biochemistry, University of Cambridge, 80 Tennis Ct Rd, Cambridge CB2 1GA, UK</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>Corresponding author: David B. Ascher, Structural Biology and Bioinformatics, Department of Biochemistry, University of Melbourne, Parkville 3052, VIC, Australia. <email>david.ascher@unimelb.edu</email></corresp>
      <corresp id="cor2"><label>∗∗</label>Corresponding author: Douglas E.V. Pires, Systems and Computational Biology, Bio21 Institute, University of Melbourne, Parkville 3052, VIC, Australia. <email>douglas.pires@unimelb.edu.au</email></corresp>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>26</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <day>03</day>
      <month>12</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>26</day>
      <month>8</month>
      <year>2021</year>
    </pub-date>
    <volume>26</volume>
    <fpage>536</fpage>
    <lpage>546</lpage>
    <history>
      <date date-type="received">
        <day>14</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>19</day>
        <month>8</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The Author(s)</copyright-statement>
      <copyright-year>2021</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <p>The emergence of high-throughput sequencing techniques has revealed a primary role of microRNAs (miRNAs) in a wide range of diseases, including cancers and neurodegenerative disorders. Understanding novel relationships between miRNAs and diseases can potentially unveil complex pathogenesis mechanisms, leading to effective diagnosis and treatment. The investigation of novel miRNA-disease associations, however, is currently costly and time consuming. Over the years, several computational models have been proposed to prioritize potential miRNA-disease associations, but with limited usability or predictive capability. In order to fill this gap, we introduce TSMDA, a novel machine-learning method that leverages target and symptom information and negative sample selection to predict miRNA-disease association. TSMDA significantly outperforms similar methods, achieving an area under the receiver operating characteristic (ROC) curve (AUC) of 0.989 and 0.982 under 5-fold cross-validation and blind test, respectively. We also demonstrate the capability of the method to uncover potential miRNA-disease associations in breast, prostate, and lung cancers, as case studies. We believe TSMDA will be an invaluable tool for the community to explore and prioritize potentially new miRNA-disease associations for further experimental characterization. The method was made available as a freely accessible and user-friendly web interface at <ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au/tsmda/" id="intref0010">http://biosig.unimelb.edu.au/tsmda/</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical abstract</title>
      <fig id="undfig1" position="anchor">
        <graphic xlink:href="fx1"/>
      </fig>
    </abstract>
    <abstract abstract-type="teaser" id="abs0020">
      <p>This work proposes a novel model, TSMDA, for predicting miRNA-disease association using miRNA-target and disease-symptom information. TSMDA also encompasses two reliable negative sample selections to effectively predict miRNA-disease associations. TSMDA is freely available as a user-friendly web server for the community to explore potential associations for further experimental miRNA characterization.</p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Keywords</title>
      <kwd>microRNA</kwd>
      <kwd>disease</kwd>
      <kwd>miRNA-disease association prediction</kwd>
      <kwd>target-based similarity</kwd>
      <kwd>symptom-based similarity</kwd>
      <kwd>cancer</kwd>
      <kwd>miRNA-target interaction</kwd>
      <kwd>XGBoost</kwd>
      <kwd>machine learning</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p id="p0010">MicroRNAs (miRNAs) are small regulatory non-coding RNAs with a typical length of 21–25 nucleotides. Human mature miRNAs control the gene expression of target messenger RNAs (mRNAs) by partially complementary base pairing with the 3′ untranslated region.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> This interaction generally results in post-transcriptional repression, occasionally leading to miRNA degradation.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Various physiological processes, such as cell proliferation and cell death, are regulated by a complex network of miRNAs.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p>
    <p id="p0015">The advent of high-throughput sequencing techniques has been contributing to the growing evidence of associations between miRNAs and diseases. Deregulation of several miRNAs is correlated with the development of multiple diseases, such as cancers and brain and cardiovascular diseases.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> For example, pancreatic carcinogenesis may occur from the upregulation of miR-21, miR-155, miR-181, miR-221, and miR-222.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Hence, understanding the relationship between miRNAs and diseases might shed light on pathogenesis, promoting miRNA-based applications such as biomarkers or drugs.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> Currently, a significant number of disease-related miRNAs are experimentally confirmed and collected in multiple databases.<xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref> Despite these significant efforts, large-scale exploration of the potential disease-miRNA associations is unfeasible, since experimental validation is laborious and costly. In this context, effective computational methods are urgently needed to suggest potential associations and guide experimental efforts.</p>
    <p id="p0020">Diverse machine-learning models have been extensively implemented to assist in exploring miRNA-disease relationships.<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> From the widely accepted assumption that phenotypically similar diseases and functionally equivalent miRNAs tend to be associated, experimentally confirmed associations can be used to identify novel associations. One model in particular, miRNA target-dysregulated network (MTDN), has been built to unveil potential cancer-related miRNAs.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> One of the posterior advances is the random forest for miRNA-disease association (RFMDA),<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> which is based on miRNA functional similarity (MISIM)<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> and disease semantic similarity,<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> as features to perform the miRNA-disease-association predictions.</p>
    <p id="p0025">Despite the remarkable effort of currently available methods, model performance was still limited by miRNA and disease similarity estimations that did not directly reflect miRNA mechanisms and disease pathogenesis. The performance improvement obtained by two additional methods, latent feature extraction for miRNA-disease association (LFEMDA)<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> and distance-based sequence similarity for miRNA-disease association (DBMDA),<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> emphasize that the introduction of biological features, such as miRNA sequence, into similarity calculation is important. A lack of actual negative samples was also a significant challenge, where various methods randomly selected negative samples from miRNA-disease pairs without confirmed associations.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> This approach likely leads to false negatives. Two previous models, non-negative samples extraction (NSEMDA)<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> and negative sample selection strategy and multi-layer perceptron (NMLPMDA),<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> have proposed alternative approaches to select reliable negative samples. NSEMDA iteratively filtered unknown samples with positive-unlabeled (PU) learning, an algorithm designed to deal with a labeling issue, where only a single class is available.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Alternatively, NMLPMDA utilized the miRNA-gene-disease network to remove likely associations.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p>
    <p id="p0030">Here we propose a novel machine-learning model that employs target- and symptom-based similarity for miRNA-disease-association prediction (TSMDA). In this study, miRNA target genes and disease symptoms were introduced to enhance similarity calculation, coupled with reliable negative sample selections based on extended miRNA-gene-disease network and modified PU learning.</p>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <sec id="sec2.1">
      <title>Feature selection</title>
      <p id="p0035">In this study, two feature selection methods, a correlation-based and forward stepwise greedy feature selection,<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> were employed to select the minimal effective subset from 1,373 features to train a highly accurate model. As a result, 13 features were chosen. This subset consists of five miRNA functional similarities, three target-based miRNA similarities, and five symptom-based disease similarities (<xref rid="tbl1" ref-type="table">Table 1</xref>). It is adopted to train and validate the extreme gradient boosting (XGBoost) model.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Selected features and corresponding biological meaning</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Feature</th><th>Category</th><th>Meaning</th></tr></thead><tbody><tr><td>1</td><td>miRNA functional similarity (MISIM)</td><td>similarity with “hsa-miR-1180-3p”</td></tr><tr><td>2</td><td>miRNA functional similarity (MISIM)</td><td>similarity with “has-miR-3179”</td></tr><tr><td>3</td><td>miRNA functional similarity (MISIM)</td><td>similarity with “hsa-miR-320c”</td></tr><tr><td>4</td><td>miRNA functional similarity (MISIM)</td><td>similarity with “hsa-miR-376b-3p”</td></tr><tr><td>5</td><td>miRNA functional similarity (MISIM)</td><td>similarity with “hsa-miR-487a-3p”</td></tr><tr><td>6</td><td>target-based miRNA similarity</td><td>similarity with “hsa-miR-127-3p”</td></tr><tr><td>7</td><td>target-based miRNA similarity</td><td>similarity with “hsa-miR-184”</td></tr><tr><td>8</td><td>target-based miRNA similarity</td><td>similarity with “hsa-miR-516a-5p”</td></tr><tr><td>9</td><td>symptom-based disease similarity</td><td>similarity with “Alopecia (D000505)”</td></tr><tr><td>10</td><td>symptom-based disease similarity</td><td>similarity with “Biliary Atresia (D001656)”</td></tr><tr><td>11</td><td>symptom-based disease similarity</td><td>similarity with “Atopic dermatitis (D003876)”</td></tr><tr><td>12</td><td>symptom-based disease similarity</td><td>similarity with “Myelodysplastic Syndromes (D009190)”</td></tr><tr><td>13</td><td>symptom-based disease similarity</td><td>similarity with “Tourette Syndrome (D005879)”</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="sec2.2">
      <title>Interpretation of the XGBoost model</title>
      <p id="p0040">Model interpretability is one of the essential aspects to consider before putting a machine learning model to use.<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref> It is crucial for explaining the accuracy of model prediction and guiding performance improvement. Despite achieving high accuracy, popular complex models, such as XGBoost and neural networks,<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref> are excessively complex for human interpretation. Different methods have been introduced to help understand the predictions in response to a lack of interpretability.<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref> SHapley Additive exPlanations (SHAP) is one of the methods designed to explain a model by examining the contribution of each feature in terms of SHAP value to a prediction.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> SHAP value is a measure of feature importance, calculated to exhibit the distribution of each feature’s impact on a prediction. The benefits of SHAP values are computational efficiency and consistency with human explanations.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></p>
      <p id="p0045">In this work, we implemented SHAP to analyze how the trained XGBoost model makes a prediction. SHAP values of 13 selected features were calculated and displayed in <xref rid="fig1" ref-type="fig">Figure 1</xref>, where features are ranked based on the average impact on model output in descending order. The most important feature is feature 4, representing the MISIM functional similarity with hsa-miR-376b. This miRNA is experimentally supported to be associated with a wide type of diseases, including adrenocortical carcinoma,<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> cerebral ischemia,<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> Graves’ disease,<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> myocardial ischemia,<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Parkinson’s disease,<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> and prostate neoplasms.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> According to a widely accepted assumption that similar miRNAs tend to be associated with phenotypically similar diseases, miRNAs with high feature 4 values will be more likely to be associated with these diseases or related conditions. This assumption is in accord with a remarkable positive correlation between feature 4 values and miRNA-disease associations in the figure. Similar trends can be clearly observed in features 6, 7, and 8 that represent target-based miRNA similarity.<fig id="fig1"><label>Figure 1</label><caption><p>Feature 4 is the most contributing feature to a prediction, showing a distinct positive correlation with a miRNA-disease association</p><p>The SHAP value for each feature in the XGBoost model was calculated. The features are ranked based on the average impact on a model prediction. One dot represents one miRNA-disease association. The values of features are represented by color, red indicating high values and blue indicating low values.</p></caption><graphic xlink:href="gr1"/></fig></p>
      <p id="p0050">Features 10, 11, and 9 are the 2nd, 3rd, and 4th most critical features, accounting for symptom-based disease similarities with biliary atresia, atopic dermatitis, and alopecia. In this case, they present an unclear correlation with miRNA-disease associations. This finding well accords with expectations, as many disease similarities are needed to be considered as a group to represent a particular disease.</p>
    </sec>
    <sec id="sec2.3">
      <title>Performance of TSMDA</title>
      <p id="p0055">We started by assessing the ability of TSMDA to predict miRNA-disease associations using The Human microRNA Disease Database (HMDD) v.2.0 database,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> assessed under different cross-validation schemes. Under 5-fold cross-validation, our model achieved an AUC of 0.989, as well as Matthews correlation coefficient (MCC), balanced accuracy (bACC), and F1 scores of 0.978, 0.989, and 0.989, respectively (<xref rid="tbl2" ref-type="table">Table 2</xref>). The method obtained comparable outcomes from 10-fold and 20-fold cross-validation, further demonstrating the robustness of the TSMDA predictive model (<xref rid="tbl2" ref-type="table">Table 2</xref>). Taking a closer look at misclassified entries in a blind test and cross-validation, we noticed that the majority are false negatives. The investigation exhibits that 27 out of 31 entries in the blind test are false negatives. However, no particular miRNA or disease is found predominantly. We further examined the contribution of each feature to misclassified predictions in a blind test with individual SHAP values (<xref rid="mmc2" ref-type="supplementary-material">Table S1</xref>). Unsurprisingly, the result suggested the features with high feature importance, especially feature 4, tend to be the main contributors to a misclassification.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>The results of TSMDA based on a blind test, 5-fold, 10-fold, and 20-fold cross-validation in HMDD v.2.0</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Methods</th><th>AUC</th><th>MCC</th><th>bACC</th><th>F1</th></tr></thead><tbody><tr><td>Blind test</td><td>0.982</td><td>0.965</td><td>0.982</td><td>0.982</td></tr><tr><td>5-fold cross-validation</td><td>0.989 ± 0.003</td><td>0.978 ± 0.005</td><td>0.989 ± 0.003</td><td>0.989 ± 0.003</td></tr><tr><td>10-fold cross-validation</td><td>0.989 ± 0.004</td><td>0.978 ± 0.008</td><td>0.989 ± 0.004</td><td>0.989 ± 0.004</td></tr><tr><td>20-fold cross-validation</td><td>0.989 ± 0.005</td><td>0.978 ± 0.010</td><td>0.989 ± 0.005</td><td>0.989 ± 0.005</td></tr></tbody></table></table-wrap></p>
      <p id="p0060">Diverse computational models have been proposed to fill the missing knowledge of miRNA-disease relationships during the past 10 years.<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> In this study, we compare the performance of TSMDA with six recent miRNA-disease-association predictors: RFMDA,<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> NSEMDA,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> ICFMDA,<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> BLHARMDA,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> GBDT-LR,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> and SwMKML.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> The selected methods are based on the same dataset, HMDD v.2.0, enabling an adequate comparison. As most methods are not publicly available for replication, only the AUC values reported in the original article were used for a comparison. As a result, our model considerably outperformed all six recent predictive models (<xref rid="fig2" ref-type="fig">Figure 2</xref>A).<fig id="fig2"><label>Figure 2</label><caption><p>Predictive performance of TSMDA</p><p>(A) TSMDA considerably outperformed six recent miRNA-disease-association predictive models in terms of area under the curve (AUC). (B) Two negative sample selections, a miRNA-gene-disease network and modified PU learning, substantially enhance the performance of TSMDA. AUC, Matthews correlation coefficient (MCC), balanced accuracy (bACC), and F1 of TSMDA model with and without negative sample were assessed in 5-fold cross-validation with an extreme gradient boosting (XGBoost) classifier.</p></caption><graphic xlink:href="gr2"/></fig></p>
      <p id="p0065">We believe one of the reasons behind the performance of TSMDA lies in the novel procedure to measure miRNA and disease similarity by considering target genes and symptoms, which directly reflect the biological nature of miRNAs and diseases. Moreover, unlike previous research that randomly selected negative samples from unknown associations,<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> TSMDA utilizes a miRNA-gene-disease network, followed by a modified PU learning, to construct more reliable negative samples (<xref rid="fig2" ref-type="fig">Figure 2</xref>B).</p>
    </sec>
    <sec id="sec2.4">
      <title>Blind test</title>
      <p id="p0070">To evaluate the generalization capabilities of TSMDA, we assessed its performance on an independent blind test of experimentally validated miRNA-disease associations from HMDD, providing an unbiased evaluation of the trained model. The model reached an AUC, MCC, bACC, and F1 of 0.982, 0.965, 0.982, and 0.982, respectively, which were consistent with the performance obtained under cross-validation (<xref rid="tbl2" ref-type="table">Table 2</xref>).</p>
    </sec>
    <sec id="sec2.5">
      <title>Predicting miRNA-disease associations in cancer</title>
      <p id="p0075">Three case studies involving prevalent cancer types (breast, prostate, and lung cancer) were employed to evaluate the capability of TSMDA of predicting potential miRNA-disease associations in a real-world scenario.</p>
      <p id="p0080">The statistics reported in the 2020 annual report of the American Cancer Society show that these cancers are among the top five cancers with the highest estimated new cases and deaths in the US population.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Breast cancer is widely known as the most prevalent cancer in females, accounting for 30% of the cases.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Similarly, prostate cancer is the most commonly found male cancer, responsible for one-fifth of the cases, while lung cancer is the second most common type of cancer in both genders.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></p>
      <p id="p0085">In the first case study, the general predictive performance of TSMDA was assessed by its ability to identify the breast, prostate, and lung cancer-related miRNAs for experimentally validated associations in dbDEMC and miRCancer.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Known associations in HMDD v.2.0 were chosen as a training dataset. The top 50 cancer-related miRNAs were ranked based on TSMDA scores and listed in <xref rid="mmc1" ref-type="supplementary-material">Tables S2–S4</xref>. Using TSMDA scores, 49, 50, and 50 of the predicted miRNAs associated with breast, prostate, and lung cancer, respectively, were experimentally confirmed by other databases.</p>
      <p id="p0090">The ability of TSMDA to predict potential associations for diseases without verified associated miRNAs was evaluated in the second case study. Known associations between the three cancer types and miRNAs in the training set of HMDD v.2.0 were removed, one cancer at a time. As a result, 49, 49, and 49 of the top 50 were validated with known associations in dbDEMC and miR2Cancer (<xref rid="mmc1" ref-type="supplementary-material">Tables S5–S7</xref>).<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref></p>
      <p id="p0095">In the third case study, miR2Disease containing 3,273 known associations between 349 miRNAs and 163 diseases was used to demonstrate our model performance on different datasets.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> miR2Disease was used to train the model, and the top 50 potential associated miRNAs predicted were investigated in dbDEMC and miR2Cancer (<xref rid="mmc1" ref-type="supplementary-material">Tables S8–S10</xref>).<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> All associations were confirmed, indicating the robustness of TSMDA to uncover potential miRNA-disease associations when considering different datasets.</p>
    </sec>
    <sec id="sec2.6">
      <title>TSMDA web server</title>
      <p id="p0100">We have made TSMDA available as an easy-to-use web server. the TSMDA web server works according to the following procedures. First, users are required to manually provide a list of miRNAs in miRBase format and a list of disease Medical Subject Heading (MeSH) IDs. This list can be provided as a file. Users also have the possibility to fill a single string for either miRNA or MeSH ID. The example can be downloaded in the TSMDA server (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). After running TSMDA, prediction results will be provided as a table, which can be downloaded as a comma-separated file. For each pair of miRNA and disease, an association confidence is shown. A higher score indicates a higher potential of association between miRNA and disease. Moreover, related evidence is given as a PMID for a pair of miRNA and disease with existing experimental support in Mammalian ncRNA-Disease Repository (MNDR) or dbDEMC.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> The TSMDA web server is available at <ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au/tsmda/" id="intref0015">http://biosig.unimelb.edu.au/tsmda/</ext-link>.<fig id="fig3"><label>Figure 3</label><caption><p>The TSMDA web server interface</p><p>(A) A list of miRNAs in miRBase IDs and diseases in MeSH IDs are required as input for the TSMDA web server. (B) The result from TSMDA is provided as a table. A higher prediction score indicates a higher probability for miRNA-disease association. If a miRNA-disease association is experimentally supported by MNDR<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> or dbDEMC,<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> evidence is provided as a PMID.</p></caption><graphic xlink:href="gr3"/></fig></p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p id="p0105">The utilization of miRNAs as diagnostic biomarkers or drugs has received growing attention,<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> due to their significant regulatory roles in various physiological processes. To enable the development of miRNA-based therapeutic applications, a wide range of studies has validated a large number of relationships between miRNAs and disease, which have provided a better understanding of miRNA regulatory mechanisms.<xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> A significant proportion of potential miRNA-disease associations are yet to be explored, and computational methods play an essential role in assisting on this task.</p>
    <p id="p0110">The proposed TSMDA prediction model has led to three major improvements for miRNA-disease-association prediction in terms of (1) miRNA similarity calculation, (2) disease similarity calculation, and (3) negative sample selection strategies. First, an approach for miRNA similarity calculation called target-based miRNA similarity was introduced. Unlike sequence or associated-disease information used in many previous methods,<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> individual miRNAs’ target genes directly reflect their unique function in molecular pathways. TSDMA has shown that by combining this method with MISIM miRNA functional similarity, they can help improve the model’s prediction power and reliability (<xref rid="fig4" ref-type="fig">Figure 4</xref>). Second, the symptom-based approach was utilized to calculate disease similarity. Several studies indicated the remarkable predictive capability of symptom-based similarity as it is associated with several molecular mechanisms,<xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref> including shared genes, protein interactions, and molecular origins. Finally, we designed modern negative sample selection approaches on TSMDA. A lack of actual negative samples has been a limitation of miRNA-disease-association studies for an extended period. In this work, two reliable methods proposed in previous research, miRNA-gene-disease network<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> and traditional PU learning,<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> were adopted and modified. A more comprehensive network was obtained in comparison with previous methods by integrating two datasets from miRTarbase and Tarbase.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> The modified PU learning approach was introduced to relieve the strong dependence on the chosen criteria of selecting reliable negative samples in the original method.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref><fig id="fig4"><label>Figure 4</label><caption><p>The introduction of miRNA functional similarity (MISIM) with target-based miRNA similarity moderately enhances TSMDA performance</p><p>AUC, MCC, bACC, and F1 in TSMDA models with three sets of features—3 target-based miRNA similarities (T) with 5 symptom-based similarities, 5 MISIM similarities (M) with 5 symptom-based similarities, and 8 target-based and MISIM miRNA similarities (T + M) with 5 symptom-based similarities—were assessed in 5-fold cross-validation with XGBoost classifier.</p></caption><graphic xlink:href="gr4"/></fig></p>
    <p id="p0115">To verify the performance of TSMDA, the method was assessed under different cross-validation schemes, as well as through an independent blind test and three case studies. The performance levels and consistency under different validation scenarios illustrate the robustness of the method in prioritizing potential miRNA-disease associations. Furthermore, we showed TSMDA has outperformed alternative state-of-the-art methods (<xref rid="fig2" ref-type="fig">Figure 2</xref>A),<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> indicating a substantial improvement from previous efforts. The model’s reliability in a real-world application was supported by the case studies on the three common cancer types. To facilitate access to the method’s capabilities and enable reproducibility, we developed a user-friendly web server to allow easy access by other researchers.</p>
    <p id="p0120">In future works, miRNA-disease-association predictions might be improved in many directions. One of the limitations of the current model is the bias in data availability. A significant proportion of experimentally validated miRNA-disease associations as well as miRNA-target gene interactions has not been confirmed. Although TSMDA has attempted to overcome this bias by introducing a unique weighting scheme, more informative data sources, such as miRNA expression profiles, should be taken into consideration. On the other hand, other molecular properties of diseases, such as related biochemical pathways, could be introduced to enhance predictive accuracy. However, the disease similarity estimation is restrained by the limitation of HMDD v.2.0, where some diseases are not found in the Disease Ontology,<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> a standardized ontology for human diseases generally used for diverse disease similarity calculations.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref><sup>,</sup><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref></p>
    <p id="p0125">Data quality is a significant hurdle in determining the success of miRNA-disease-association prediction models. As future work, a practical method that utilizes other biological information to guide a reliable negative sample selection may be proposed to increase the model effectiveness. Furthermore, miRNA expression profiles retrieved from public databases, such as The Cancer Genome Atlas, can be utilized to improve data quality. Removing confirmed miRNA-disease associations with low confidence according to differential expression analysis may significantly improve data reliability.</p>
  </sec>
  <sec id="sec4">
    <title>Materials and methods</title>
    <sec id="sec4.1">
      <title>TSMDA general workflow</title>
      <p id="p0130">The proposed pipeline consists of five main steps (<xref rid="fig5" ref-type="fig">Figure 5</xref>). First, confirmed miRNA-disease associations were obtained from HMDD v.2.0.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> In the following step, feature engineering is performed and three sets of similarities constructed: MISIM,<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> target-based miRNA similarity, and symptom-based disease similarity. These were integrated into feature vectors, representing pairs of miRNA-disease associations. Subsequently, reliable negative samples were selected using miRNA-gene-disease network and modified PU learning. Following that, a subset of relevant features is chosen by correlation-based and forward stepwise greedy feature selection.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> An extreme gradient boosting classifier (XGBoost) was employed to create a prediction model for potential associations. The method’s performance was assessed using both internal (5-fold, 10-fold, and 20-fold cross-validation) and external validation (blind test and three case studies).<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref><fig id="fig5"><label>Figure 5</label><caption><p>TSMDA: Predicting miRNA-disease associations</p><p>The development of TSMDA is divided into five steps: (1) data collection, (2) feature vector construction, (3) negative sample selection, (4) feature selection, and (5) model training and evaluation.</p></caption><graphic xlink:href="gr5"/></fig></p>
    </sec>
    <sec id="sec4.2">
      <title>Data collection: Human miRNA-disease associations</title>
      <p id="p0135">Experimentally validated human miRNA-disease associations were retrieved from HMDD v.2.0.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> The dataset contains 5,430 associations between 495 miRNAs and 383 diseases. Given this dataset, a vector <italic>V</italic> was built to describe the associations between miRNA and disease as follows:<disp-formula id="fd1"><label>(Equation 1)</label><mml:math id="M1" altimg="si1.gif"><mml:mrow><mml:mspace width="0.25em"/><mml:mi>V</mml:mi><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo linebreak="badbreak">+</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mo linebreak="badbreak">×</mml:mo><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="M2" altimg="si2.gif"><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M3" altimg="si3.gif"><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:math></inline-formula> are the number of miRNAs and diseases in HMDD v.2.0, respectively, and <inline-formula><mml:math id="M4" altimg="si4.gif"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is equal to one (1) if miRNA <italic>i</italic> and disease <italic>j</italic> are experimentally associated, and zero (0), otherwise.</p>
    </sec>
    <sec id="sec4.3">
      <title>miRNA functional similarity</title>
      <p id="p0140">The MISIM used in this research was proposed by Wang et al.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> due to its relative simplicity and decent capability to represent miRNA similarity in a number of studies.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref>, <xref rid="bib20" ref-type="bibr">20</xref>, <xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> The data of known miRNA-disease associations was utilized to assess miRNA similarity based on the assumption that miRNAs with similar functions are more likely to be associated with pathologically similar diseases. We retrieved miRNA functional similarity of miRNAs found in HMDD v.2.0 from the Cui Lab repository. The miRNA functional similarity matrix (MFS) describing the pairwise similarities among 495 miRNAs was constructed.</p>
    </sec>
    <sec id="sec4.4">
      <title>Target-based miRNA similarity</title>
      <p id="p0145">Despite a satisfactory contribution to miRNA-disease predictions, incomplete data of validated associations still limited the performance of MISIM. To address this limitation, other data types should be considered to enhance miRNA similarity representation and mitigate biases. Two modern methods, LFEMDA and DBMDA, proposed sequence-based approaches to estimate miRNA similarity. The improved accuracy indicated the usefulness of biological features.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref></p>
      <p id="p0150">In this work, biological information of miRNA targets was introduced to determine miRNA similarity. miRNAs perform a regulatory function via complementary base pairing with several mRNAs. Thus, miRNAs with similar target genes are more likely to have similar functions in molecular pathways. Here, we utilized the numbers of shared target genes to assess miRNA similarity. The experimentally validated miRNA-target interactions were available at miRTarBase and TarBase.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> miRTarBase consists of 553,168 interactions between 3,775 miRNAs and 22,336 target genes, whereas TarBase contains 422,614 interactions between 1,084 miRNAs and 20,790 target genes. The interactions related to miRNAs found in HMDD v.2.0 were extracted and merged, producing the dataset of 397,402 interactions between 489 miRNAs and 21,284 genes. Across all 495 miRNAs in the HMDD v.2.0, six missing miRNAs were proved by miRBase to be experimental errors.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref></p>
      <p id="p0155">The information of shared target genes between miRNAs was utilized to calculate miRNA similarity. The 21,284-dimensional vector <inline-formula><mml:math id="M5" altimg="si2.gif"><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula> described target genes for miRNA <inline-formula><mml:math id="M6" altimg="si5.gif"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> was created as:<disp-formula id="fd2"><label>(Equation 2)</label><mml:math id="M7" altimg="si6.gif"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math id="M8" altimg="si7.gif"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denotes the strength of the interaction between miRNA <inline-formula><mml:math id="M9" altimg="si5.gif"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> and target gene <inline-formula><mml:math id="M10" altimg="si8.gif"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula>. It is calculated by taking the prevalence of target genes in the dataset into consideration. The strength of interaction between a pair of miRNA <inline-formula><mml:math id="M11" altimg="si5.gif"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> and target gene <inline-formula><mml:math id="M12" altimg="si8.gif"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> is equal to log 2 of term frequency of target gene if they are interacting, otherwise equal to zero as follows:<disp-formula id="fd3"><label>(Equation 3)</label><mml:math id="M13" altimg="si9.gif"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:msub><mml:mi>g</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>F</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.25em"/><mml:msub><mml:mi>T</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.25em"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mn>0</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>In the equation, <inline-formula><mml:math id="M14" altimg="si10.gif"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> is a term frequency of a target gene. <inline-formula><mml:math id="M15" altimg="si11.gif"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M16" altimg="si12.gif"><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> refer to miRNA <inline-formula><mml:math id="M17" altimg="si5.gif"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> and target gene <inline-formula><mml:math id="M18" altimg="si13.gif"><mml:mrow><mml:mi>j</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula></p>
      <p id="p0160">In the end, cosine similarity was employed to assess the target-based miRNA similarity between the arrays representing the miRNAs.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Cosine similarity is a standard metric used to compute the directional similarity between two vectors by capturing orientational differences. The advantage of the cosine similarity is the computation irrespective of vectors’ sizes. miRNA similarity was calculated as stored in a target-based miRNA similarity matrix <inline-formula><mml:math id="M19" altimg="si14.gif"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>T</mml:mi><mml:mi>M</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>.</p>
    </sec>
    <sec id="sec4.5">
      <title>Symptom-based disease similarity</title>
      <p id="p0165">Several studies demonstrated a close correspondence between the resemblance of molecular pathogenesis (e.g., shared gene, protein-protein interactions, and molecular origin) and the phenotypic similarity in clinical symptoms.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref><sup>,</sup><xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> On this basis, Zhou et al.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> proposed the novel symptom-based disease similarity calculation that can be applied to create a phenotype network profile for discovering molecular targets for drug repurposing.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref><sup>,</sup><xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> This approach has displayed a robust correlation between calculated similarity and molecular-level disease components. The unique advantage of this method is a wide availability of directly observable clinical phenotypes in various diseases. For this reason, TSMDA aimed to implement a symptom-based approach to measure disease similarity.</p>
      <p id="p0170">The co-occurrences of diseases and symptoms in PubMed were used to characterize each disease in terms of clinical phenotypes. First, the 383 diseases from HMDD v.2.0 were mapped to 328 MeSH identifiers.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> For each disease, its MeSH ID was used as a query to search for co-occurrences with 481 symptoms (2020th updated), categorized by PubMed. Disease <italic>i</italic> can be described by a 481-dimensional vector as follows:<disp-formula id="fd4"><label>(Equation 4)</label><mml:math id="M20" altimg="si15.gif"><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>481</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><inline-formula><mml:math id="M21" altimg="si16.gif"><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> quantifies the intensity of the co-occurrence between disease <inline-formula><mml:math id="M22" altimg="si5.gif"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> and symptom <inline-formula><mml:math id="M23" altimg="si8.gif"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula>. According to the bias where some symptoms such as pain are comparatively more abundant, the intensity was estimated considering the term frequency-inverse document frequency (TF-IDF).<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> It is calculated from absolute co-occurrence <inline-formula><mml:math id="M24" altimg="si17.gif"><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> as the following equation:<disp-formula id="fd5"><label>(Equation 5)</label><mml:math id="M25" altimg="si18.gif"><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:msub><mml:mi>W</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mspace width="0.25em"/></mml:mrow></mml:msub><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mfrac><mml:mi>N</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where <italic>N</italic> denotes the number of diseases in HMDD v.2.0, while <inline-formula><mml:math id="M26" altimg="si19.gif"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> represents the number of diseases where symptom <inline-formula><mml:math id="M27" altimg="si8.gif"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> appears. Same as target-based miRNA similarity, the cosine similarity was also employed to measure the directional similarity between symptom-described vectors for each disease.<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> The symptom-based disease similarity among 495 diseases was represented as a symptom-based disease similarity matrix <inline-formula><mml:math id="M28" altimg="si20.gif"><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>D</mml:mi><mml:mi>S</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>.</p>
    </sec>
    <sec id="sec4.6">
      <title>miRNA and disease similarity integration</title>
      <p id="p0175">We obtained 1,373-dimensional feature vectors describing 189,585 possible pairs of miRNAs and diseases in HMDD v.2.0 from the integration of MISIM miRNA functional similarity, target-based miRNA similarity, and symptom-based disease similarity. The feature vectors <inline-formula><mml:math id="M29" altimg="si21.gif"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> representing miRNA <inline-formula><mml:math id="M30" altimg="si5.gif"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> and disease <inline-formula><mml:math id="M31" altimg="si8.gif"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> were constructed as follows:<disp-formula id="fd6"><label>(Equation 6)</label><mml:math id="M32" altimg="si22.gif"><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="badbreak">=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mi>d</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>s</mml:mi><mml:mi>d</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>Here,<inline-formula><mml:math id="M33" altimg="si23.gif"><mml:mrow><mml:mspace width="0.25em"/><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M34" altimg="si24.gif"><mml:mrow><mml:mi>t</mml:mi><mml:mi>m</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>.</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denote MISIM and target-based miRNA similarity between miRNA<inline-formula><mml:math id="M35" altimg="si25.gif"><mml:mrow><mml:mspace width="0.25em"/><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> and miRNA<inline-formula><mml:math id="M36" altimg="si26.gif"><mml:mrow><mml:mspace width="0.25em"/><mml:mi>m</mml:mi></mml:mrow></mml:math></inline-formula>, whereas <inline-formula><mml:math id="M37" altimg="si27.gif"><mml:mrow><mml:mi>s</mml:mi><mml:mi>d</mml:mi><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> is the symptom-based disease similarity between disease <inline-formula><mml:math id="M38" altimg="si8.gif"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula>and disease <inline-formula><mml:math id="M39" altimg="si28.gif"><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:math></inline-formula>. <inline-formula><mml:math id="M40" altimg="si29.gif"><mml:mrow><mml:mi>n</mml:mi><mml:mi>M</mml:mi></mml:mrow></mml:math></inline-formula>and <inline-formula><mml:math id="M41" altimg="si30.gif"><mml:mrow><mml:mi>n</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:math></inline-formula> are numbers of miRNAs and diseases in HMDD v.2.0.</p>
    </sec>
    <sec id="sec4.7">
      <title>Negative sample selection</title>
      <p id="p0180">Negative sample selection is undeniably one of the most crucial processes in miRNA-disease-association modeling due to the absence of true negative samples in the database. A variety of negative sample selection strategies have been explored to address this issue.</p>
      <p id="p0185">The general standard procedure is to obtain negative samples by a random selection from unlabeled miRNA-disease associations.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> This approach expects the ideal situation where unconfirmed pairs can be arbitrarily considered as not existing, which may not be valid, negatively affecting the reliability of negative samples. NSEMDA<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> has proposed alternative strategies that utilize a traditional PU learning model<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> to train the model and remove unreliable negative samples iteratively. In contrast, NMLPMDA suggested a distinct method that focused on the construction of a miRNA-gene-disease network.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> Pairs of miRNA and disease that show no relationship were selected as reliable negative samples. The remarkable accuracy of these methods illustrates the potential to prioritize reliable negative samples. However, there is still room for improvement.</p>
      <p id="p0190">TSMDA employed a miRNA-gene-disease network, followed by modified PU learning to form a robust negative sample selection. The methods were further improved by extending the size of the network and replacing the original PU learning with a modified algorithm. In details, 115,891,964 verified gene-disease associations between 21,671 genes and 30,170 diseases were acquired from DisGENET v.7.0.<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> They were integrated with the aforementioned miRNA-target gene interactions from miRTarbase<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> and Tarbase,<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> forming the miRNA-gene-disease network. Pairs of miRNA and disease sharing the same gene in the network were considered as potential miRNA-disease associations. Unknown associations in our dataset were then mapped to the network to filter out the potential associations. From 184,155 unknown associations, only 20,716 associations (∼10%) are selected as promising negative samples.</p>
      <p id="p0195">To increasingly refine the negative samples, modified PU learning<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> employing an iterative pruning strategy was introduced. It was initially proposed to mitigate the heavy dependence on the chosen criteria of reliable negative sample selection,<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> resulting in more reliable negative samples. In this work, 20% of known associations in HMDD v.2.0 were separated from the dataset and used as positive samples in PU learning to prevent overfitting from a bias toward a dataset, while the remaining negative samples were negative samples. Random forest (RF) classifier<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> was selected to train a model in an iterative manner because of the robustness to overfitting and less requirement for parameter tuning. Negative samples with low confidence scores were removed in each turn, otherwise retained in the dataset.</p>
      <p id="p0200">During the first loop, the RF classifier was trained to remove a large proportion of negative samples that were highly likely to be positive samples. Merely 1% of negative samples classified as positives or negatives, but with a probability lower than 95%, they were eliminated. Due to this strict condition, the remaining negative samples will be comparatively more reliable and suitable for training subsequent models. In the following loops, we aimed for a slight reduction of negative samples in each loop. An RF classifier was similarly implemented; however, the hyperparameter was set in order to limit the model complexity, allowing iterative pruning. The numbers of estimators and maximum depth were reduced to 20 and 3. Only negative samples classified as positives were removed each step. The process was run until the number of reliable samples was the same as known associations.</p>
    </sec>
    <sec id="sec4.8">
      <title>Feature selection</title>
      <p id="p0205">After the negative sample selection, feature selection was used to define a better set of features, so redundancy and noise are removed or diminished, computation time and model complexity are reduced, and overfitting is less likely to happen.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> In several miRNA-disease-association models, employing a proper feature selection technique leads to a substantially increased predictive performance.<xref rid="bib60" ref-type="bibr">60</xref>, <xref rid="bib61" ref-type="bibr">61</xref>, <xref rid="bib62" ref-type="bibr">62</xref> TSMDA utilizes two feature selection means, a correlation-based<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> and forward stepwise greedy feature selection.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr">63</xref>, <xref rid="bib64" ref-type="bibr">64</xref>, <xref rid="bib65" ref-type="bibr">65</xref></p>
      <p id="p0210">Initially, Pearson's correlation coefficients (PCCs) between every pair of features were calculated and represented as a heatmap in <xref rid="mmc1" ref-type="supplementary-material">Figure S1</xref>. It was apparent that multiple features are redundant, so some can be discarded without reducing model accuracy. We conducted a performance evaluation to examine the optimal cutoff for PCC values (<xref rid="mmc1" ref-type="supplementary-material">Figure S2</xref>). As a result, the cutoff of 0.6 was selected. If a PCC between features is higher than 0.6, only one feature is randomly retained. Consequently, the number of features was drastically reduced from 1,373 to 97.</p>
      <p id="p0215">Forward stepwise greedy feature selection was used to scale down the remaining dimensions by selecting the best combination of features.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> The process begins with zero features selected. The most useful feature contributing the most to the performance was included one at a time. In each step, 10-fold cross-validation with XGBoost<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> was performed, then evaluated with MCC (<xref rid="mmc1" ref-type="supplementary-material">Figure S3</xref>). At the end, 13 features (<xref rid="tbl1" ref-type="table">Table 1</xref>) were chosen as the best combination required to train a highly accurate model. The subset of features contained five miRNA functional similarities, three target-based miRNA similarities, and five symptom-based disease similarities.</p>
    </sec>
    <sec id="sec4.9">
      <title>XGBoost classifier</title>
      <p id="p0220">XGBoost<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> is one of the most widely used tree-based boosting algorithms, where a set of weak classifiers are combined to form a strong classifier sequentially. In each iteration, misclassification errors of a previous classifier were corrected to create a more accurate model. In contrast to other boosting algorithms, XGBoost has several enhancements in regularization, parallelization, handling missing values, dropout methods, and others.</p>
      <p id="p0225">In this work, this algorithm has been shown to be the one with best performances in terms of miRNA-disease-association predictions in preliminary experiments (see <xref rid="mmc1" ref-type="supplementary-material">Table S11</xref>). The final feature vectors represented by the selected 13 features are adopted to train and validate the XGBoost classification model.</p>
    </sec>
    <sec sec-type="data-availability" id="sec4.10">
      <title>Availability of data and materials</title>
      <p id="p0230">The datasets used in this work are available at <ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au/tsmda/data" id="intref0020">http://biosig.unimelb.edu.au/tsmda/data</ext-link>.</p>
    </sec>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Wahid</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Shehzad</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Khan</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>Y.Y.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs: synthesis, mechanism, function, and recent clinical trials</article-title>
        <source>Biochim. Biophys. Acta</source>
        <volume>1803</volume>
        <year>2010</year>
        <fpage>1231</fpage>
        <lpage>1243</lpage>
        <pub-id pub-id-type="pmid">20619301</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Bagga</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bracht</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Massirer</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Holtz</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Eachus</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Pasquinelli</surname>
            <given-names>A.E.</given-names>
          </name>
        </person-group>
        <article-title>Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation</article-title>
        <source>Cell</source>
        <volume>122</volume>
        <year>2005</year>
        <fpage>553</fpage>
        <lpage>563</lpage>
        <pub-id pub-id-type="pmid">16122423</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Deng</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Calin</surname>
            <given-names>G.A.</given-names>
          </name>
          <name>
            <surname>Croce</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Coukos</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>Mechanisms of microRNA deregulation in human cancer</article-title>
        <source>Cell Cycle</source>
        <volume>7</volume>
        <year>2008</year>
        <fpage>2643</fpage>
        <lpage>2646</lpage>
        <pub-id pub-id-type="pmid">18719391</pub-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Gurha</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNAs in cardiovascular disease</article-title>
        <source>Curr. Opin. Cardiol.</source>
        <volume>31</volume>
        <year>2016</year>
        <fpage>249</fpage>
        <lpage>254</lpage>
        <pub-id pub-id-type="pmid">26885771</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hsu</surname>
            <given-names>P.K.</given-names>
          </name>
          <name>
            <surname>Karayiorgou</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Gogos</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction</article-title>
        <source>Neurobiol. Dis.</source>
        <volume>46</volume>
        <year>2012</year>
        <fpage>291</fpage>
        <lpage>301</lpage>
        <pub-id pub-id-type="pmid">22406400</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Kochman</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis</article-title>
        <source>Yearbook of Gastroenterology</source>
        <volume>2007</volume>
        <year>2007</year>
        <fpage>63</fpage>
        <lpage>64</lpage>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Schwarzenbach</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Milde-Langosch</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Steinbach</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Müller</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Pantel</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients</article-title>
        <source>Breast Cancer Res. Treat.</source>
        <volume>134</volume>
        <year>2012</year>
        <fpage>933</fpage>
        <lpage>941</lpage>
        <pub-id pub-id-type="pmid">22350790</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Mar-Aguilar</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Mendoza-Ramírez</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Malagón-Santiago</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Espino-Silva</surname>
            <given-names>P.K.</given-names>
          </name>
          <name>
            <surname>Santuario-Facio</surname>
            <given-names>S.K.</given-names>
          </name>
          <name>
            <surname>Ruiz-Flores</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Rodríguez-Padilla</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Reséndez-Pérez</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Serum circulating microRNA profiling for identification of potential breast cancer biomarkers</article-title>
        <source>Dis. Markers</source>
        <volume>34</volume>
        <year>2013</year>
        <fpage>163</fpage>
        <lpage>169</lpage>
        <pub-id pub-id-type="pmid">23334650</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Rupaimoole</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Slack</surname>
            <given-names>F.J.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA therapeutics: towards a new era for the management of cancer and other diseases</article-title>
        <source>Nat. Rev. Drug Discov.</source>
        <volume>16</volume>
        <year>2017</year>
        <fpage>203</fpage>
        <lpage>222</lpage>
        <pub-id pub-id-type="pmid">28209991</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Qiu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Tu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Geng</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>Q.</given-names>
          </name>
        </person-group>
        <article-title>HMDD v2.0: a database for experimentally supported human microRNA and disease associations</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>42</volume>
        <issue>D1</issue>
        <year>2014</year>
        <fpage>D1070</fpage>
        <lpage>D1074</lpage>
        <pub-id pub-id-type="pmid">24194601</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Teschendorff</surname>
            <given-names>A.E.</given-names>
          </name>
        </person-group>
        <article-title>dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>45</volume>
        <issue>D1</issue>
        <year>2017</year>
        <fpage>D812</fpage>
        <lpage>D818</lpage>
        <pub-id pub-id-type="pmid">27899556</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>miRCancer: a microRNA-cancer association database constructed by text mining on literature</article-title>
        <source>Bioinformatics</source>
        <volume>29</volume>
        <year>2013</year>
        <fpage>638</fpage>
        <lpage>644</lpage>
        <pub-id pub-id-type="pmid">23325619</pub-id>
      </element-citation>
    </ref>
    <ref id="bib13">
      <label>13</label>
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.X.</given-names>
          </name>
          <name>
            <surname>Lv</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.S.</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Shao</surname>
            <given-names>T.T.</given-names>
          </name>
          <name>
            <surname>Huo</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zou</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Q.L.</given-names>
          </name>
        </person-group>
        <article-title>Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: case study of prostate cancer</article-title>
        <source>Mol. Cancer Ther.</source>
        <volume>10</volume>
        <year>2011</year>
        <fpage>1857</fpage>
        <lpage>1866</lpage>
        <pub-id pub-id-type="pmid">21768329</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>14</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>You</surname>
            <given-names>Z.H.</given-names>
          </name>
        </person-group>
        <article-title>Novel Human miRNA-Disease Association Inference Based on Random Forest</article-title>
        <source>Mol. Ther. Nucleic Acids</source>
        <volume>13</volume>
        <year>2018</year>
        <fpage>568</fpage>
        <lpage>579</lpage>
        <pub-id pub-id-type="pmid">30439645</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>15</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Che</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>Predicting MiRNA-Disease Association by Latent Feature Extraction with Positive Samples</article-title>
        <source>Genes (Basel)</source>
        <volume>10</volume>
        <year>2019</year>
        <fpage>80</fpage>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>16</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>You</surname>
            <given-names>Z.H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L.P.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Z.W.</given-names>
          </name>
        </person-group>
        <article-title>DBMDA: A Unified Embedding for Sequence-Based miRNA Similarity Measure with Applications to Predict and Validate miRNA-Disease Associations</article-title>
        <source>Mol. Ther. Nucleic Acids</source>
        <volume>19</volume>
        <year>2020</year>
        <fpage>602</fpage>
        <lpage>611</lpage>
        <pub-id pub-id-type="pmid">31931344</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>17</label>
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>An integrated framework for the identification of potential miRNA-disease association based on novel negative samples extraction strategy</article-title>
        <source>RNA Biol.</source>
        <volume>16</volume>
        <year>2019</year>
        <fpage>257</fpage>
        <lpage>269</lpage>
        <pub-id pub-id-type="pmid">30646823</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>18</label>
      <mixed-citation publication-type="other" id="sref18">Li, N., Duan, G., Yan, C., Wu, F.X., and Wang, J. (2020). MiRNA-Disease Associations Prediction Based on Negative Sample Selection and Multi-layer Perceptron. In Bioinformatics Research and Applications. ISBRA 2020, Volume 12304, Z. Cai, I. Mandoiu, G. Narasimhan, P. Skums, and X. Guo, eds., Lecture Notes in Computer Science (Cham: Springer).</mixed-citation>
    </ref>
    <ref id="bib19">
      <label>19</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Bian</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>Predict MiRNA-Disease Association with Collaborative Filtering</article-title>
        <source>Neuroinformatics</source>
        <volume>16</volume>
        <year>2018</year>
        <fpage>363</fpage>
        <lpage>372</lpage>
        <pub-id pub-id-type="pmid">29948843</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>20</label>
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Predicting microRNA-disease associations using bipartite local models and hubness-aware regression</article-title>
        <source>RNA Biol.</source>
        <volume>15</volume>
        <year>2018</year>
        <fpage>1192</fpage>
        <lpage>1205</lpage>
        <pub-id pub-id-type="pmid">30196756</pub-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>21</label>
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Azim</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>Predicting potential miRNA-disease associations by combining gradient boosting decision tree with logistic regression</article-title>
        <source>Comput. Biol. Chem.</source>
        <volume>85</volume>
        <year>2020</year>
        <fpage>107200</fpage>
        <pub-id pub-id-type="pmid">32058946</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>22</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Pan</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Xiao</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Self-Weighted Multi-Kernel Multi-Label Learning for Potential miRNA-Disease Association Prediction</article-title>
        <source>Mol. Ther. Nucleic Acids</source>
        <volume>17</volume>
        <year>2019</year>
        <fpage>414</fpage>
        <lpage>423</lpage>
        <pub-id pub-id-type="pmid">31319245</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>23</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>Q.</given-names>
          </name>
        </person-group>
        <article-title>Inferring the human microRNA functional similarity and functional network based on microRNA-associated diseases</article-title>
        <source>Bioinformatics</source>
        <volume>26</volume>
        <year>2010</year>
        <fpage>1644</fpage>
        <lpage>1650</lpage>
        <pub-id pub-id-type="pmid">20439255</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>24</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Xuan</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Teng</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>Prediction of microRNAs Associated with Human Diseases Based on Weighted k Most Similar Neighbors</article-title>
        <source>PLoS ONE</source>
        <volume>8</volume>
        <year>2013</year>
        <fpage>e70204</fpage>
        <pub-id pub-id-type="pmid">23950912</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>25</label>
      <element-citation publication-type="book" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>W.S.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>P.S.</given-names>
          </name>
          <name>
            <surname>Heights</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <part-title>Partially Supervised Classification of Text Documents</part-title>
        <year>1998</year>
        <ext-link ext-link-type="uri" xlink:href="https://www.cs.uic.edu/%7Eliub/S-EM/unlabelled.pdf" id="intref0030">https://www.cs.uic.edu/∼liub/S-EM/unlabelled.pdf</ext-link>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>26</label>
      <element-citation publication-type="book" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Rochio</surname>
            <given-names>J.J.</given-names>
          </name>
        </person-group>
        <part-title>Relevant feedback in information retrieval</part-title>
        <person-group person-group-type="editor">
          <name>
            <surname>Salton</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <source>The Smart Retrieval System: Experiments in Automatic Document Processing</source>
        <year>1971</year>
        <publisher-name>Prentice Hall Inc.</publisher-name>
        <publisher-loc>Englewood Cliffs, NJ</publisher-loc>
        <fpage>313</fpage>
        <lpage>323</lpage>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>27</label>
      <element-citation publication-type="book" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Hall</surname>
            <given-names>M.A.</given-names>
          </name>
        </person-group>
        <part-title>Correlation-based Feature Selection for Discrete and Numeric Class Machine Learning. Proceedings of the Seventeenth International Conference on Machine Learning</part-title>
        <year>2000</year>
        <fpage>359</fpage>
        <lpage>366</lpage>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>28</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Deng</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Weng</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Feature selection for text classification: A review</article-title>
        <source>Multimedia Tools Appl.</source>
        <volume>78</volume>
        <year>2019</year>
        <fpage>3797</fpage>
        <lpage>3816</lpage>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>29</label>
      <element-citation publication-type="book" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Guestrin</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <part-title>XGBoost: A Scalable Tree Boosting System. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining</part-title>
        <year>2016</year>
        <fpage>785</fpage>
        <lpage>794</lpage>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>30</label>
      <element-citation publication-type="book" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Lundberg</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>S.I.</given-names>
          </name>
        </person-group>
        <part-title>A Unified Approach to Interpreting Model Predictions</part-title>
        <person-group person-group-type="editor">
          <name>
            <surname>Guyon</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Luxburg</surname>
            <given-names>U.V.</given-names>
          </name>
          <name>
            <surname>Bengio</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wallach</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Fergus</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Vishwanathan</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Garnett</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <source>NeurIPS, <italic>30</italic></source>
        <year>2017</year>
        <publisher-name>Curran Associates, Inc.</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>31</label>
      <element-citation publication-type="book" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>M.T.</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Guestrin</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <part-title>Why should I trust you?: Explaining the predictions of any classifier. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining</part-title>
        <year>2016</year>
        <fpage>1135</fpage>
        <lpage>1144</lpage>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>32</label>
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Erik</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Igor</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Explaining prediction models and individual predictions with feature contributions</article-title>
        <source>Knowl. Inf. Syst.</source>
        <volume>41</volume>
        <year>2014</year>
        <fpage>647</fpage>
        <lpage>665</lpage>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>33</label>
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Schmidhuber</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Deep learning in neural networks: an overview</article-title>
        <source>Neural Netw.</source>
        <volume>61</volume>
        <year>2015</year>
        <fpage>85</fpage>
        <lpage>117</lpage>
        <pub-id pub-id-type="pmid">25462637</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>34</label>
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Iliopoulos</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Bimpaki</surname>
            <given-names>E.I.</given-names>
          </name>
          <name>
            <surname>Nesterova</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Stratakis</surname>
            <given-names>C.A.</given-names>
          </name>
        </person-group>
        <article-title>MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling</article-title>
        <source>Cancer Res.</source>
        <volume>69</volume>
        <year>2009</year>
        <fpage>3278</fpage>
        <lpage>3282</lpage>
        <pub-id pub-id-type="pmid">19351815</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>35</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G.B.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.H.</given-names>
          </name>
        </person-group>
        <article-title>miR-376b-5p regulates angiogenesis in cerebral ischemia</article-title>
        <source>Mol. Med. Rep.</source>
        <volume>10</volume>
        <year>2014</year>
        <fpage>527</fpage>
        <lpage>535</lpage>
        <pub-id pub-id-type="pmid">24789343</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>36</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Ning</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Differential microRNA expression in peripheral blood mononuclear cells from Graves’ disease patients</article-title>
        <source>J. Clin. Endocrinol. Metab.</source>
        <volume>97</volume>
        <year>2012</year>
        <fpage>E968</fpage>
        <lpage>E972</lpage>
        <pub-id pub-id-type="pmid">22456620</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>37</label>
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>Pan</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Qi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>M3 subtype of muscarinic acetylcholine receptor promotes cardioprotection via the suppression of miR-376b-5p</article-title>
        <source>PLoS ONE</source>
        <volume>7</volume>
        <year>2012</year>
        <fpage>e32571</fpage>
        <pub-id pub-id-type="pmid">22396777</pub-id>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>38</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Vargas-Medrano</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Garza</surname>
            <given-names>N.T.</given-names>
          </name>
          <name>
            <surname>Segura-Ulate</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Perez</surname>
            <given-names>R.G.</given-names>
          </name>
        </person-group>
        <article-title>Up-regulation of protective neuronal MicroRNAs by FTY720 and novel FTY720-derivatives</article-title>
        <source>Neurosci. Lett.</source>
        <volume>690</volume>
        <year>2019</year>
        <fpage>178</fpage>
        <lpage>180</lpage>
        <pub-id pub-id-type="pmid">30359694</pub-id>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>39</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Nam</surname>
            <given-names>R.K.</given-names>
          </name>
          <name>
            <surname>Wallis</surname>
            <given-names>C.J.D.</given-names>
          </name>
          <name>
            <surname>Amemiya</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Benatar</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Seth</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Identification of a novel MicroRNA panel associated with metastasis following radical prostatectomy for prostate cancer</article-title>
        <source>Anticancer Res.</source>
        <volume>38</volume>
        <year>2018</year>
        <fpage>5027</fpage>
        <lpage>5034</lpage>
        <pub-id pub-id-type="pmid">30194146</pub-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>40</label>
      <element-citation publication-type="book" id="sref40">
        <person-group person-group-type="author">
          <collab>American Cancer Society</collab>
        </person-group>
        <part-title>Cancer Facts &amp; Figures 2020</part-title>
        <year>2020</year>
        <ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf" id="intref0035">https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf</ext-link>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>41</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Jiang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Hao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Juan</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Teng</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>miR2Disease: a manually curated database for microRNA deregulation in human disease</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>37</volume>
        <issue>Suppl 1</issue>
        <year>2009</year>
        <fpage>D98</fpage>
        <lpage>D104</lpage>
        <pub-id pub-id-type="pmid">18927107</pub-id>
      </element-citation>
    </ref>
    <ref id="bib42">
      <label>42</label>
      <element-citation publication-type="journal" id="sref42">
        <person-group person-group-type="author">
          <name>
            <surname>Ning</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>MNDR v3.0: mammal ncRNA-disease repository with increased coverage and annotation</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>49</volume>
        <issue>D1</issue>
        <year>2021</year>
        <fpage>D160</fpage>
        <lpage>D164</lpage>
        <pub-id pub-id-type="pmid">32833025</pub-id>
      </element-citation>
    </ref>
    <ref id="bib43">
      <label>43</label>
      <element-citation publication-type="journal" id="sref43">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Menche</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Barabási</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Sharma</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Human symptoms-disease network</article-title>
        <source>Nat. Commun.</source>
        <volume>5</volume>
        <year>2014</year>
        <fpage>4212</fpage>
        <pub-id pub-id-type="pmid">24967666</pub-id>
      </element-citation>
    </ref>
    <ref id="bib44">
      <label>44</label>
      <element-citation publication-type="journal" id="sref44">
        <person-group person-group-type="author">
          <name>
            <surname>Casas</surname>
            <given-names>A.I.</given-names>
          </name>
          <name>
            <surname>Hassan</surname>
            <given-names>A.A.</given-names>
          </name>
          <name>
            <surname>Larsen</surname>
            <given-names>S.J.</given-names>
          </name>
          <name>
            <surname>Gomez-Rangel</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Elbatreek</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kleikers</surname>
            <given-names>P.W.M.</given-names>
          </name>
          <name>
            <surname>Guney</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Egea</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>López</surname>
            <given-names>M.G.</given-names>
          </name>
          <name>
            <surname>Baumbach</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>H.H.H.W.</given-names>
          </name>
        </person-group>
        <article-title>From single drug targets to synergistic network pharmacology in ischemic stroke</article-title>
        <source>Proc. Natl. Acad. Sci. USA</source>
        <volume>116</volume>
        <year>2019</year>
        <fpage>7129</fpage>
        <lpage>7136</lpage>
        <pub-id pub-id-type="pmid">30894481</pub-id>
      </element-citation>
    </ref>
    <ref id="bib45">
      <label>45</label>
      <element-citation publication-type="journal" id="sref45">
        <person-group person-group-type="author">
          <name>
            <surname>Cheng</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Desai</surname>
            <given-names>R.J.</given-names>
          </name>
          <name>
            <surname>Handy</surname>
            <given-names>D.E.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Schneeweiss</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Barabási</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Loscalzo</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Network-based approach to prediction and population-based validation of in silico drug repurposing</article-title>
        <source>Nat. Commun.</source>
        <volume>9</volume>
        <year>2018</year>
        <fpage>2691</fpage>
        <pub-id pub-id-type="pmid">30002366</pub-id>
      </element-citation>
    </ref>
    <ref id="bib46">
      <label>46</label>
      <element-citation publication-type="journal" id="sref46">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>H.Y.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>Y.C.D.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>K.Y.</given-names>
          </name>
          <name>
            <surname>Shrestha</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>H.C.</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Y.G.</given-names>
          </name>
          <name>
            <surname>Jin</surname>
            <given-names>C.N.</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>48</volume>
        <issue>D1</issue>
        <year>2020</year>
        <fpage>D148</fpage>
        <lpage>D154</lpage>
        <pub-id pub-id-type="pmid">31647101</pub-id>
      </element-citation>
    </ref>
    <ref id="bib47">
      <label>47</label>
      <element-citation publication-type="journal" id="sref47">
        <person-group person-group-type="author">
          <name>
            <surname>Karagkouni</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Paraskevopoulou</surname>
            <given-names>M.D.</given-names>
          </name>
          <name>
            <surname>Chatzopoulos</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Vlachos</surname>
            <given-names>I.S.</given-names>
          </name>
          <name>
            <surname>Tastsoglou</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Kanellos</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Papadimitriou</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kavakiotis</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Maniou</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Skoufos</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>46</volume>
        <issue>D1</issue>
        <year>2018</year>
        <fpage>D239</fpage>
        <lpage>D245</lpage>
        <pub-id pub-id-type="pmid">29156006</pub-id>
      </element-citation>
    </ref>
    <ref id="bib48">
      <label>48</label>
      <element-citation publication-type="journal" id="sref48">
        <person-group person-group-type="author">
          <name>
            <surname>Hernández Fusilier</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Montes-y-Gómez</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rosso</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Guzmán Cabrera</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Detecting positive and negative deceptive opinions using PU-learning</article-title>
        <source>Inf. Process. Manage.</source>
        <volume>51</volume>
        <year>2015</year>
        <fpage>433</fpage>
        <lpage>443</lpage>
      </element-citation>
    </ref>
    <ref id="bib49">
      <label>49</label>
      <element-citation publication-type="journal" id="sref49">
        <person-group person-group-type="author">
          <name>
            <surname>Schriml</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Arze</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Nadendla</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>Y.W.W.</given-names>
          </name>
          <name>
            <surname>Mazaitis</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Felix</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Kibbe</surname>
            <given-names>W.A.</given-names>
          </name>
        </person-group>
        <article-title>Disease Ontology: a backbone for disease semantic integration</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>40</volume>
        <issue>D1</issue>
        <year>2012</year>
        <fpage>D940</fpage>
        <lpage>D946</lpage>
        <pub-id pub-id-type="pmid">22080554</pub-id>
      </element-citation>
    </ref>
    <ref id="bib50">
      <label>50</label>
      <element-citation publication-type="journal" id="sref50">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L.G.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>G.R.</given-names>
          </name>
          <name>
            <surname>He</surname>
            <given-names>Q.Y.</given-names>
          </name>
        </person-group>
        <article-title>DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis</article-title>
        <source>Bioinformatics</source>
        <volume>31</volume>
        <year>2015</year>
        <fpage>608</fpage>
        <lpage>609</lpage>
        <pub-id pub-id-type="pmid">25677125</pub-id>
      </element-citation>
    </ref>
    <ref id="bib51">
      <label>51</label>
      <element-citation publication-type="journal" id="sref51">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Rao</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>DOSim: an R package for similarity between diseases based on Disease Ontology</article-title>
        <source>BMC Bioinformatics</source>
        <volume>12</volume>
        <year>2011</year>
        <fpage>266</fpage>
        <pub-id pub-id-type="pmid">21714896</pub-id>
      </element-citation>
    </ref>
    <ref id="bib52">
      <label>52</label>
      <element-citation publication-type="book" id="sref52">
        <person-group person-group-type="author">
          <name>
            <surname>Géron</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <part-title>Hands-on Machine Learning with Scikit-Learn, Keras &amp; TensorFlow</part-title>
        <edition>Second Edition</edition>
        <year>2019</year>
        <publisher-name>O’Reilly Media</publisher-name>
        <publisher-loc>Sebastopol, CA</publisher-loc>
      </element-citation>
    </ref>
    <ref id="bib53">
      <label>53</label>
      <element-citation publication-type="journal" id="sref53">
        <person-group person-group-type="author">
          <name>
            <surname>Kozomara</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Birgaoanu</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Griffiths-Jones</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>miRBase: from microRNA sequences to function</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>47</volume>
        <issue>D1</issue>
        <year>2019</year>
        <fpage>D155</fpage>
        <lpage>D162</lpage>
        <pub-id pub-id-type="pmid">30423142</pub-id>
      </element-citation>
    </ref>
    <ref id="bib54">
      <label>54</label>
      <element-citation publication-type="journal" id="sref54">
        <person-group person-group-type="author">
          <name>
            <surname>Singhal</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Modern information retrieval: A brief overview</article-title>
        <source>IEEE Data Eng. Bull.</source>
        <volume>24</volume>
        <year>2001</year>
        <fpage>35</fpage>
        <lpage>43</lpage>
      </element-citation>
    </ref>
    <ref id="bib55">
      <label>55</label>
      <element-citation publication-type="journal" id="sref55">
        <person-group person-group-type="author">
          <name>
            <surname>Freudenberg</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Propping</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>A similarity-based method for genome-wide prediction of disease-relevant human genes</article-title>
        <source>Bioinformatics</source>
        <volume>18</volume>
        <issue>Suppl 2</issue>
        <year>2002</year>
        <fpage>S110</fpage>
        <lpage>S115</lpage>
        <pub-id pub-id-type="pmid">12385992</pub-id>
      </element-citation>
    </ref>
    <ref id="bib56">
      <label>56</label>
      <element-citation publication-type="journal" id="sref56">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Ning</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>Community of protein complexes impacts disease association</article-title>
        <source>Eur. J. Hum. Genet.</source>
        <volume>20</volume>
        <year>2012</year>
        <fpage>1162</fpage>
        <lpage>1167</lpage>
        <pub-id pub-id-type="pmid">22549411</pub-id>
      </element-citation>
    </ref>
    <ref id="bib57">
      <label>57</label>
      <element-citation publication-type="journal" id="sref57">
        <person-group person-group-type="author">
          <name>
            <surname>Lipscomb</surname>
            <given-names>C.E.</given-names>
          </name>
        </person-group>
        <article-title>Medical subject headings (MeSH)</article-title>
        <source>Bull. Med. Libr. Assoc.</source>
        <volume>88</volume>
        <year>2000</year>
        <fpage>265</fpage>
        <lpage>266</lpage>
        <pub-id pub-id-type="pmid">10928714</pub-id>
      </element-citation>
    </ref>
    <ref id="bib58">
      <label>58</label>
      <element-citation publication-type="journal" id="sref58">
        <person-group person-group-type="author">
          <name>
            <surname>Piñero</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ramírez-Anguita</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Saüch-Pitarch</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ronzano</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Centeno</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Sanz</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Furlong</surname>
            <given-names>L.I.</given-names>
          </name>
        </person-group>
        <article-title>The DisGeNET knowledge platform for disease genomics: 2019 update</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>48</volume>
        <issue>D1</issue>
        <year>2020</year>
        <fpage>D845</fpage>
        <lpage>D855</lpage>
        <pub-id pub-id-type="pmid">31680165</pub-id>
      </element-citation>
    </ref>
    <ref id="bib59">
      <label>59</label>
      <element-citation publication-type="book" id="sref59">
        <person-group person-group-type="author">
          <name>
            <surname>Ho</surname>
            <given-names>T.K.</given-names>
          </name>
        </person-group>
        <series>Random Decision Forest. Proceedings of the 3rd International Conference on Document Analysis and Recognition</series>
        <volume>1</volume>
        <year>1995</year>
        <fpage>278</fpage>
        <lpage>282</lpage>
      </element-citation>
    </ref>
    <ref id="bib60">
      <label>60</label>
      <element-citation publication-type="journal" id="sref60">
        <person-group person-group-type="author">
          <name>
            <surname>Peng</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hui</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Shang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>A learning-based framework for miRNA-disease association identification using neural networks</article-title>
        <source>bioRxiv</source>
        <year>2018</year>
        <pub-id pub-id-type="doi">10.1101/276048</pub-id>
      </element-citation>
    </ref>
    <ref id="bib61">
      <label>61</label>
      <element-citation publication-type="journal" id="sref61">
        <person-group person-group-type="author">
          <name>
            <surname>Yao</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Zhan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Kwoh</surname>
            <given-names>C.K.</given-names>
          </name>
        </person-group>
        <article-title>An improved random forest-based computational model for predicting novel miRNA-disease associations</article-title>
        <source>BMC Bioinformatics</source>
        <volume>20</volume>
        <year>2019</year>
        <fpage>624</fpage>
        <pub-id pub-id-type="pmid">31795954</pub-id>
      </element-citation>
    </ref>
    <ref id="bib62">
      <label>62</label>
      <element-citation publication-type="journal" id="sref62">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Yin</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Ensemble of decision tree reveals potential miRNA-disease associations</article-title>
        <source>PLoS Comput. Biol.</source>
        <volume>15</volume>
        <year>2019</year>
        <fpage>e1007209</fpage>
        <pub-id pub-id-type="pmid">31329575</pub-id>
      </element-citation>
    </ref>
    <ref id="bib63">
      <label>63</label>
      <element-citation publication-type="journal" id="sref63">
        <person-group person-group-type="author">
          <name>
            <surname>Rodrigues</surname>
            <given-names>C.H.M.</given-names>
          </name>
          <name>
            <surname>Pires</surname>
            <given-names>D.E.V.</given-names>
          </name>
          <name>
            <surname>Ascher</surname>
            <given-names>D.B.</given-names>
          </name>
        </person-group>
        <article-title>DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations</article-title>
        <source>Protein Sci.</source>
        <volume>30</volume>
        <year>2021</year>
        <fpage>60</fpage>
        <lpage>69</lpage>
        <pub-id pub-id-type="pmid">32881105</pub-id>
      </element-citation>
    </ref>
    <ref id="bib64">
      <label>64</label>
      <element-citation publication-type="journal" id="sref64">
        <person-group person-group-type="author">
          <name>
            <surname>Pires</surname>
            <given-names>D.E.V.</given-names>
          </name>
          <name>
            <surname>Ascher</surname>
            <given-names>D.B.</given-names>
          </name>
        </person-group>
        <article-title>mycoCSM: Using Graph-based signatures to Identify Safe Potent hits against mycobacteria</article-title>
        <source>J. Chem. Inf. Model.</source>
        <volume>60</volume>
        <year>2020</year>
        <fpage>3450</fpage>
        <lpage>3456</lpage>
        <pub-id pub-id-type="pmid">32615035</pub-id>
      </element-citation>
    </ref>
    <ref id="bib65">
      <label>65</label>
      <element-citation publication-type="journal" id="sref65">
        <person-group person-group-type="author">
          <name>
            <surname>Myung</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Pires</surname>
            <given-names>D.E.V.</given-names>
          </name>
          <name>
            <surname>Ascher</surname>
            <given-names>D.B.</given-names>
          </name>
        </person-group>
        <article-title>mmCSM-AB: guiding rational antibody engineering through multiple point mutations</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>48</volume>
        <issue>W1</issue>
        <year>2020</year>
        <fpage>W125</fpage>
        <lpage>W131</lpage>
        <pub-id pub-id-type="pmid">32432715</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec2" sec-type="supplementary-material">
    <title>Supplemental information</title>
    <p id="p0255">
      <supplementary-material content-type="local-data" id="mmc1">
        <caption>
          <title>Document S1. Tables S2–S11 and Figures S1–S3</title>
        </caption>
        <media xlink:href="mmc1.pdf"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc2">
        <caption>
          <title>Table S1. The contribution of each feature to a prediction based on SHAP values in misclassified entries in a blind test</title>
        </caption>
        <media xlink:href="mmc2.xlsx"/>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="mmc3">
        <caption>
          <title>Document S2. Article plus supplemental information</title>
        </caption>
        <media xlink:href="mmc3.pdf"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p id="p0235">K.U. was supported by the <funding-source id="gs1">Melbourne Research Scholarship</funding-source>. A.G.C.d.S. acknowledges the <funding-source id="gs2">Joe White Bequest Fellowship</funding-source> for its support. D.B.A. and D.E.V.P. were funded by a Newton Fund RCUK-CONFAP Grant awarded by <funding-source id="gs3">The Medical Research Council</funding-source> (MR/M026302/1). D.B.A. was supported by the <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source> (grant 093167/Z/10/Z), the <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/100012698</institution-id><institution>Jack Brockhoff Foundation</institution></institution-wrap></funding-source> (JBF 4186, 2016), and an Investigator Grant from the <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000925</institution-id><institution>National Health and Medical Research Council (NHMRC) of Australia</institution></institution-wrap></funding-source> (GNT1174405). Supported in part by the <funding-source id="gs7">Victorian Government’s Operational Infrastructure Support Program</funding-source>.</p>
    <sec id="sec5">
      <title>Author contributions</title>
      <p id="p0240">K.U. prepared the dataset, designed and conducted the experiment, and wrote the manuscript with support and advice from A.G.C.d.S., A.A., D.E.V.P., and D.B.A. The web server was designed and established by A.G.C.d.S. The project was conceived, designed, and supervised by D.B.A. All the authors read and approved the final manuscript.</p>
    </sec>
    <sec sec-type="COI-statement" id="sec6">
      <title>Declaration of interests</title>
      <p id="p0245">The authors declare no competing interests.</p>
    </sec>
  </ack>
  <fn-group>
    <fn id="appsec1" fn-type="supplementary-material">
      <p id="p0250">Supplemental information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.omtn.2021.08.016" id="intref0025">https://doi.org/10.1016/j.omtn.2021.08.016</ext-link>.</p>
    </fn>
  </fn-group>
</back>
